Activation of the CaSR with positive allosteric CaSR modulators (calcimimetics) enhanced several inflammatory pathways in CaSR-transfected colon cancer cells, while treatment with negative allosteric CaSR modulators (calcilytics) prevented this upregulation [13,14]. Here, CASR is linked to malignant colon neoplasm.